Healthcare / BiotechnologyShenzhen
$12.90
-0.28 (-2.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $78.9M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
N/A
•EV/EBITDA
24.5x
↑ROE
-4.2%
↓Gross Margin
15.0%
↓Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.1%
FCF CAGR
+262.3%
FCF margin
7.8%
FCF / Net income
-1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.02B · net income $-73.1M · FCF $78.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.02B | $1.02B | $970.6M | $1.28B | $1.31B |
| Net Income | $-73.1M | $-73.1M | $-88.8M | $45.6M | $42.0M |
| EBITDA | $119.7M | $119.7M | $102.8M | $264.7M | $248.0M |
| EPS | -0.39 | -0.39 | -0.47 | 0.25 | 0.24 |
| Gross Margin | 15.0% | 15.0% | 19.1% | 22.3% | 20.8% |
| Operating Margin | 0.3% | 0.3% | -0.8% | 6.6% | 6.4% |
| Net Margin | -7.2% | -7.2% | -9.1% | 3.6% | 3.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.41 | 0.39 | 0.41 |
| Current Ratio | 1.21 | 1.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $78.9M | $78.9M | $128.9M | $-186.9M | $1.7M |
| Returns | |||||
| ROE | -4.2% | -4.2% | -4.8% | 2.3% | 2.4% |
| Valuation | |||||
| P/E | — | — | — | 77.76 | 59.74 |
| EV/EBITDA | 24.46 | 24.46 | 40.39 | 15.49 | 12.17 |
| P/B | 1.37 | 1.37 | 1.98 | 1.76 | 1.46 |
| Growth & Yield | |||||
| Revenue Growth | 4.8% | 4.8% | -24.2% | -2.5% | — |
| EPS Growth | 17.0% | 17.0% | -288.0% | 4.2% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.47 → -0.39
Residual
-32.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.